The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current t...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0570-8 |
id |
doaj-ac146a36143540ed83d59ae4ac9773f4 |
---|---|
record_format |
Article |
spelling |
doaj-ac146a36143540ed83d59ae4ac9773f42020-11-25T00:41:50ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262019-04-017111410.1186/s40425-019-0570-8The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activationAnne Månsson Kvarnhammar0Niina Veitonmäki1Karin Hägerbrand2Anna Dahlman3Karin Enell Smith4Sara Fritzell5Laura von Schantz6Mia Thagesson7Doreen Werchau8Kristine Smedenfors9Maria Johansson10Anna Rosén11Ida Åberg12Magnus Winnerstam13Eva Nyblom14Karin Barchan15Christina Furebring16Per Norlén17Peter Ellmark18Alligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAlligator Bioscience ABAbstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current treatment regimens may limit their use. Thus, there is a medical need for new CTLA-4 targeting therapies with improved benefit-risk profile. Methods ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody generated by linking an optimized version of the Ig-like V-type domain of human CD86, a natural CTLA-4 ligand, to an agonistic OX40 antibody. In vitro evaluation of T-cell activation and T regulatory cell (Treg) depletion was performed using purified cells from healthy human donors or cell lines. In vivo anti-tumor responses were studied using human OX40 transgenic (knock-in) mice with established syngeneic tumors. Tumors and spleens from treated mice were analyzed for CD8+ T cell and Treg frequencies, T-cell activation markers and tumor localization using flow cytometry. Results ATOR-1015 induces T-cell activation and Treg depletion in vitro. Treatment with ATOR-1015 reduces tumor growth and improves survival in several syngeneic tumor models, including bladder, colon and pancreas cancer models. It is further demonstrated that ATOR-1015 induces tumor-specific and long-term immunological memory and enhances the response to PD-1 inhibition. Moreover, ATOR-1015 localizes to the tumor area where it reduces the frequency of Tregs and increases the number and activation of CD8+ T cells. Conclusions By targeting CTLA-4 and OX40 simultaneously, ATOR-1015 is directed to the tumor area where it induces enhanced immune activation, and thus has the potential to be a next generation CTLA-4 targeting therapy with improved clinical efficacy and reduced toxicity. ATOR-1015 is also expected to act synergistically with anti-PD-1/PD-L1 therapy. The pre-clinical data support clinical development of ATOR-1015, and a first-in-human trial has started (NCT03782467).http://link.springer.com/article/10.1186/s40425-019-0570-8CTLA-4OX40Regulatory T cellSolid tumors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anne Månsson Kvarnhammar Niina Veitonmäki Karin Hägerbrand Anna Dahlman Karin Enell Smith Sara Fritzell Laura von Schantz Mia Thagesson Doreen Werchau Kristine Smedenfors Maria Johansson Anna Rosén Ida Åberg Magnus Winnerstam Eva Nyblom Karin Barchan Christina Furebring Per Norlén Peter Ellmark |
spellingShingle |
Anne Månsson Kvarnhammar Niina Veitonmäki Karin Hägerbrand Anna Dahlman Karin Enell Smith Sara Fritzell Laura von Schantz Mia Thagesson Doreen Werchau Kristine Smedenfors Maria Johansson Anna Rosén Ida Åberg Magnus Winnerstam Eva Nyblom Karin Barchan Christina Furebring Per Norlén Peter Ellmark The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation Journal for ImmunoTherapy of Cancer CTLA-4 OX40 Regulatory T cell Solid tumors |
author_facet |
Anne Månsson Kvarnhammar Niina Veitonmäki Karin Hägerbrand Anna Dahlman Karin Enell Smith Sara Fritzell Laura von Schantz Mia Thagesson Doreen Werchau Kristine Smedenfors Maria Johansson Anna Rosén Ida Åberg Magnus Winnerstam Eva Nyblom Karin Barchan Christina Furebring Per Norlén Peter Ellmark |
author_sort |
Anne Månsson Kvarnhammar |
title |
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
title_short |
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
title_full |
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
title_fullStr |
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
title_full_unstemmed |
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation |
title_sort |
ctla-4 x ox40 bispecific antibody ator-1015 induces anti-tumor effects through tumor-directed immune activation |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2019-04-01 |
description |
Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current treatment regimens may limit their use. Thus, there is a medical need for new CTLA-4 targeting therapies with improved benefit-risk profile. Methods ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody generated by linking an optimized version of the Ig-like V-type domain of human CD86, a natural CTLA-4 ligand, to an agonistic OX40 antibody. In vitro evaluation of T-cell activation and T regulatory cell (Treg) depletion was performed using purified cells from healthy human donors or cell lines. In vivo anti-tumor responses were studied using human OX40 transgenic (knock-in) mice with established syngeneic tumors. Tumors and spleens from treated mice were analyzed for CD8+ T cell and Treg frequencies, T-cell activation markers and tumor localization using flow cytometry. Results ATOR-1015 induces T-cell activation and Treg depletion in vitro. Treatment with ATOR-1015 reduces tumor growth and improves survival in several syngeneic tumor models, including bladder, colon and pancreas cancer models. It is further demonstrated that ATOR-1015 induces tumor-specific and long-term immunological memory and enhances the response to PD-1 inhibition. Moreover, ATOR-1015 localizes to the tumor area where it reduces the frequency of Tregs and increases the number and activation of CD8+ T cells. Conclusions By targeting CTLA-4 and OX40 simultaneously, ATOR-1015 is directed to the tumor area where it induces enhanced immune activation, and thus has the potential to be a next generation CTLA-4 targeting therapy with improved clinical efficacy and reduced toxicity. ATOR-1015 is also expected to act synergistically with anti-PD-1/PD-L1 therapy. The pre-clinical data support clinical development of ATOR-1015, and a first-in-human trial has started (NCT03782467). |
topic |
CTLA-4 OX40 Regulatory T cell Solid tumors |
url |
http://link.springer.com/article/10.1186/s40425-019-0570-8 |
work_keys_str_mv |
AT annemanssonkvarnhammar thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT niinaveitonmaki thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinhagerbrand thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT annadahlman thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinenellsmith thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT sarafritzell thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT lauravonschantz thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT miathagesson thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT doreenwerchau thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT kristinesmedenfors thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT mariajohansson thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT annarosen thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT idaaberg thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT magnuswinnerstam thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT evanyblom thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinbarchan thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT christinafurebring thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT pernorlen thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT peterellmark thectla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT annemanssonkvarnhammar ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT niinaveitonmaki ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinhagerbrand ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT annadahlman ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinenellsmith ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT sarafritzell ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT lauravonschantz ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT miathagesson ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT doreenwerchau ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT kristinesmedenfors ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT mariajohansson ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT annarosen ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT idaaberg ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT magnuswinnerstam ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT evanyblom ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT karinbarchan ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT christinafurebring ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT pernorlen ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation AT peterellmark ctla4xox40bispecificantibodyator1015inducesantitumoreffectsthroughtumordirectedimmuneactivation |
_version_ |
1725285288374173696 |